Drugs / HPV 16/18 VLP AS04
HPV 16/18 VLP AS04
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01548118 | Feb → Oct 2012 | human papilloma virus infection | Shanghai Zerun Biotechnology Co.,Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT01263327 | Dec 2010 → Jul 2011 | cervical cancer | Xiamen University | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02740777 | Feb → Nov 2016 | cervical intraepithelial neoplasia, human papilloma virus infection | Shanghai Zerun Biotechnology Co.,Ltd | Completed | No outcome recorded |
| Phase 2 | NCT01356823 | Mar → Dec 2011 | cervical cancer, cervical intraepithelial neoplasia | Xiamen University | Completed | No outcome recorded |
| Phase 2 | NCT00120848 | Nov 2003 → Jul 2007 | human papilloma virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 34 trials · 1 met primary | ||||||
| Phase 3 | NCT02733068 | Nov 2014 → Jul 2019 | cervical intraepithelial neoplasia, human papilloma virus infection | Shanghai Zerun Biotechnology Co.,Ltd | Completed | Met primary |
| Phase 3 | NCT00485732 | Jun 2007 → Mar 2008 | human papilloma virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00345878 | Sep 2006 → Dec 2007 | human papilloma virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00306241 | Mar 2006 → Jun 2007 | human papilloma virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00572000 | Nov 2007 → Jun 2008 | — | National Institute for Control of Vaccine and Biologicals | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00231413 Comparator | Mar 2005 → Mar 2006 | human papilloma virus infection | GlaxoSmithKline | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-05-27 | GlaxoSmithKline | Regulatory China approves Cervarix two-dose vaccine schedule for girls aged 9 to 14 against certain types of cancer-causing human papillomavirus gsk.com ↗
GSK plc (LSE/NYSE: GSK) announced today that a two-dose schedule for its HPV vaccine Cervarix [Human Papillomavirus bivalent (types 16, 18) Vaccine, Recombinant)] has been approved by China’s NMPA for girls aged 9 to 14. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-05-27 | GlaxoSmithKline | China approves Cervarix two-dose vaccine schedule for girls aged 9 to 14 against certain types of cancer-causing human papillomavirus gsk.com ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPV 16/18 VLP AS04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00120848 ↗ |
| Known as | Cervarix TM | “HPV-16/18 VLP/AS04 vaccine (Cervarix TM)” NCT00485732 ↗1“HPV-16/18 L1 VLP AS04 (Cervarix TM)” NCT00345878 ↗ |
| Known as | HPV 16/18 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01263327 ↗ |
| Known as | HPV 16/18 bivalent vaccine | “Participants would intramuscularly receive 30μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.” NCT01356823 ↗ |
| Known as | HPV 16/18 L1 AS04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00231413 ↗ |
| Known as | HPV-16/18 L1 VLP AS04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00306241 ↗ |
| Known as | HPV-16/18 L1 VLP AS04 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00572000 ↗ |
| Known as | HPV-16/18 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02740777 ↗ |
| Known as | HPV-16/18 VLP/AS04 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00485732 ↗ |
| Known as | HPV-2 | “BACKGROUND: Affordable HPV vaccines are needed to accelerate elimination of cervical cancer. We evaluated the efficacy, safety, and immunogenicity of a recombinant bivalent...” PMID 41413453 ↗ Dec 2025 |
| Modality | Vaccine | “HPV vaccine” NCT00120848 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT00231413 ↗ |